Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives
Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It accounts for 15%–20% of all breast cancers and is associated with an aggressive evolution and poor outcomes with the maj...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | International Journal of Breast Cancer |
| Online Access: | http://dx.doi.org/10.1155/2020/8209173 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566039727046656 |
|---|---|
| author | Karima Oualla Loay Kassem Lamiae Nouiakh Lamiae Amaadour Zineb Benbrahim Samia Arifi Nawfel Mellas |
| author_facet | Karima Oualla Loay Kassem Lamiae Nouiakh Lamiae Amaadour Zineb Benbrahim Samia Arifi Nawfel Mellas |
| author_sort | Karima Oualla |
| collection | DOAJ |
| description | Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It accounts for 15%–20% of all breast cancers and is associated with an aggressive evolution and poor outcomes with the majority of recurrences and deaths occurring in the first 5 years. Chemotherapy remains the mainstay of treatment in the absence of effective targets, but the good understanding of immune tumor microenvironment, the identification of immune-related targets, and the role of tumor-infiltrating lymphocytes (TILs) in TNBC has allowed to develop promising immunotherapeutic strategies for this unique subset of breast cancer. Recently, immunotherapy is being extensively explored in TNBC and clinical trials have shown promising results. In this article, we tried to explain the rationale and mechanisms of targeting the immune system in TNBC, to report the results from recent clinical trials that put immunotherapy as a new standard of care in TNBC in addition to ongoing trials and future directions in the next decade. |
| format | Article |
| id | doaj-art-01490f38a5fa408b9f35f59a9bfe5f36 |
| institution | Kabale University |
| issn | 2090-3170 2090-3189 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Breast Cancer |
| spelling | doaj-art-01490f38a5fa408b9f35f59a9bfe5f362025-02-03T01:05:10ZengWileyInternational Journal of Breast Cancer2090-31702090-31892020-01-01202010.1155/2020/82091738209173Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future PerspectivesKarima Oualla0Loay Kassem1Lamiae Nouiakh2Lamiae Amaadour3Zineb Benbrahim4Samia Arifi5Nawfel Mellas6Medical Oncology Department, Hassan II University Hospital, Sidi Mohamed Ben Abdellah University, Fes, MoroccoClinical Oncology Department, Kasr Al-Ainy School of Medicine, Cairo University, Giza, EgyptMedical Oncology Department, Hassan II University Hospital, Sidi Mohamed Ben Abdellah University, Fes, MoroccoMedical Oncology Department, Hassan II University Hospital, Sidi Mohamed Ben Abdellah University, Fes, MoroccoMedical Oncology Department, Hassan II University Hospital, Sidi Mohamed Ben Abdellah University, Fes, MoroccoMedical Oncology Department, Hassan II University Hospital, Sidi Mohamed Ben Abdellah University, Fes, MoroccoMedical Oncology Department, Hassan II University Hospital, Sidi Mohamed Ben Abdellah University, Fes, MoroccoTriple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It accounts for 15%–20% of all breast cancers and is associated with an aggressive evolution and poor outcomes with the majority of recurrences and deaths occurring in the first 5 years. Chemotherapy remains the mainstay of treatment in the absence of effective targets, but the good understanding of immune tumor microenvironment, the identification of immune-related targets, and the role of tumor-infiltrating lymphocytes (TILs) in TNBC has allowed to develop promising immunotherapeutic strategies for this unique subset of breast cancer. Recently, immunotherapy is being extensively explored in TNBC and clinical trials have shown promising results. In this article, we tried to explain the rationale and mechanisms of targeting the immune system in TNBC, to report the results from recent clinical trials that put immunotherapy as a new standard of care in TNBC in addition to ongoing trials and future directions in the next decade.http://dx.doi.org/10.1155/2020/8209173 |
| spellingShingle | Karima Oualla Loay Kassem Lamiae Nouiakh Lamiae Amaadour Zineb Benbrahim Samia Arifi Nawfel Mellas Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives International Journal of Breast Cancer |
| title | Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives |
| title_full | Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives |
| title_fullStr | Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives |
| title_full_unstemmed | Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives |
| title_short | Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives |
| title_sort | immunotherapeutic approaches in triple negative breast cancer state of the art and future perspectives |
| url | http://dx.doi.org/10.1155/2020/8209173 |
| work_keys_str_mv | AT karimaoualla immunotherapeuticapproachesintriplenegativebreastcancerstateoftheartandfutureperspectives AT loaykassem immunotherapeuticapproachesintriplenegativebreastcancerstateoftheartandfutureperspectives AT lamiaenouiakh immunotherapeuticapproachesintriplenegativebreastcancerstateoftheartandfutureperspectives AT lamiaeamaadour immunotherapeuticapproachesintriplenegativebreastcancerstateoftheartandfutureperspectives AT zinebbenbrahim immunotherapeuticapproachesintriplenegativebreastcancerstateoftheartandfutureperspectives AT samiaarifi immunotherapeuticapproachesintriplenegativebreastcancerstateoftheartandfutureperspectives AT nawfelmellas immunotherapeuticapproachesintriplenegativebreastcancerstateoftheartandfutureperspectives |